Novartis Receives European Commission Approval For Itvisma® For Spinal Muscular Atrophy (SMA)

NOVARTIS AG SIX:NOVN:

• NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR ITVISMA® FOR SPINAL MUSCULAR ATROPHY (SMA)

• NOVARTIS AG - ITVISMA IS ONE-TIME FIXED DOSE GENE THERAPY FOR SMA

• NOVARTIS AG - GENE REPLACEMENT THERAPIES NOW ELIGIBLE IN EU FOR SMA ACROSS ALL AGE GROUPS

• NOVARTIS AG - STEER AND STRENGTH STUDIES SHOW CLINICALLY MEANINGFUL BENEFIT FOR SMA PATIENTS

• NOVARTIS AG - ITVISMA BECOMES FIRST GENE REPLACEMENT THERAPY APPROVED FOR BROAD SMA POPULATION IN EU